Outcome of Transplant Recipients Infected with Omicron BA.1 and BA.2: A Single-Center Retrospective Study in Saudi Arabia
AuthorsAlshukairi, Abeer N.
Abumelha, Khalid Y.
Albishi, Ghadeer E.
Alraddadi, Basem M.
Al Hroub, Mohammad K.
Ibrahim, Suzan M. Nagash
Al Musawa, Mohammed
Habahab, Wael T.
Alhamlan, Fatimah S.
KAUST DepartmentPathogen Genomics Group, Bioscience Program, BESE Division, King Abdullah University of Science and Technology (KAUST), Thuwal, Kingdom of Saudi Arabia
Biological and Environmental Science and Engineering (BESE) Division
KAUST Grant NumberBAS/1/1020-01-01
Permanent link to this recordhttp://hdl.handle.net/10754/686928
MetadataShow full item record
AbstractThe outcome of transplant recipients is variable depending on the study population, vaccination status and COVID-19 variants. Our aim was to study the impact of Omicron subvariants on the mortality of transplant recipients. We reviewed the results of SARS-CoV-2 whole genome sequence of random isolates collected from 29 December 2021 until 17 May 2022 in King Faisal Specialist Hospital and Research center, Jeddah (KFSHRC-J), Saudi Arabia performed as hospital genomic surveillance program for COVID-19 variants. We included 25 transplant patients infected with confirmed Omicron variants.17 (68%) and 8 (32%) patients had Omicron BA.1 and BA.2, respectively. 12 (68%) patients had renal transplants. Only 36% of patients received three doses of COVID-19 vaccines. 23 (92%) patients required hospitalization. 20 (80%) patients survived and 6 (25%) required intensive care unit (ICU) admission. Among ICU patients, 66.7% were more than 50 years, 50% had two to three comorbidities and 5 out of 6 (83%) died. The mortality of transplant patients infected with Omicron variants in our cohort was higher than other centers as a limited number of patients received booster vaccines. Optimizing booster vaccination is the most efficient method to improve the mortality of COVID-19 in transplant recipients recognizing the inefficacy of monoclonal antibodies in the presence of SARS-CoV-2 emerging variants. We did not show a difference in mortality in transplant patients infected with Omicron BA.1 and BA.2 knowing the limitation of our sample size.
CitationAlshukairi, A. N., Aldabbagh, Y., Adroub, S. A., Mourier, T., Abumelha, K. Y., Albishi, G. E., Alraddadi, B. M., Al Hroub, M. K., El-Saed, A., Ibrahim, S. M. N., Al Musawa, M., Almasari, A., Habahab, W. T., Alhamlan, F. S., Al-Omari, A., Pain, A., & Dada, A. (2023). Outcome of Transplant Recipients Infected with Omicron BA.1 and BA.2: A Single-Center Retrospective Study in Saudi Arabia. Journal of Epidemiology and Global Health. https://doi.org/10.1007/s44197-023-00084-6
SponsorsThe whole genome sequence work was supported by a faculty baseline fund (BAS/1/1020-01-01), King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia and King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia: COVID19 grant 2200009.We would like to thank the support of our institutions, King Faisal Specialist hospital and Research Center in Jeddah and Riyadh, King Abdullah University of Science and Technology (KAUST), Thuwal and Dr Sulaiman Al-Habib Medical Group, Riyadh, Saudi Arabia.
PublisherSpringer Science and Business Media LLC
Except where otherwise noted, this item's license is described as Archived with thanks to Journal of Epidemiology and Global Health under a Creative Commons license, details at: https://creativecommons.org/licenses/by/4.0